Sugi Predict

Sugi Predict / Compounds / SCHEMBL1011432

SCHEMBL1011432

SCHEMBL1011432

Cc1ccc2cccnc2c1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.56
▸ PDE10A Q9Y233 1/20 0.56
▸ LMNA P02545 5/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ TDP1 Q9NUW8 5/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPT P10636 7/20 0.48
▸ HTT P42858 4/20 0.48
▸ CCR1 P32246 3/20 0.48
▸ CCR5 P51681 3/20 0.48
▸ CCR8 P51685 3/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ HSP90AA1 P07900 2/20 0.48
▸ NFKB1 P19838 2/20 0.48
▸ GMNN O75496 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MMP2 P08253 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10614589 0.82 MEN1 (0.62) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL11973739 0.81 PDE10A (0.53) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10277488 0.80 PDE10A (0.56) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10690325 0.80 PDE10A (0.56) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10615047 0.80 PDE10A (0.56) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL2672220 0.80 MAPT (0.56) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10277357 0.80 PDE10A (0.51) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10615121 0.80 PDE10A (0.51) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL11973750 0.80 PDE10A (0.51) TSHRPDE10ALMNASMN1; SMN2MEN1
SCHEMBL10614565 0.78 MAPT (0.50) TSHRPDE10ALMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102649786-B Preparation method for 2, 4-diamino-5-(8-dimethylamino-7-methyl-5-quinolyl Methyl)-2, 4-(1H and 3H) pyrimidine ZHENGZHOU FUYUAN ANIMAL PHARMACEUTICAL CO LTD 2014-08-27 — — CN claimed
CN-102649786-A Preparation method for 2, 4-diamino-5-(8-dimethylamino-7-methyl-5-quinolyl Methyl)-2, 4-(1H and 3H) pyrimidine ZHENGZHOU FUYUAN ANIMAL PHARMACEUTICAL CO LTD 2012-08-29 — — CN claimed
CN-117865886-B N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof 中国药科大学 2024-05-10 — — CN disclosed
CN-117865886-A N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof 中国药科大学 2024-04-12 — — CN disclosed
US-11655203-B2 Nitration ETH ZURICH (CH) 2023-05-23 — — US disclosed
CN-113387823-B Anthranilic acid and derivative thereof, and synthetic method and application thereof 华东师范大学 2022-07-08 — — CN disclosed
US-20220009875-A1 NITRATION ETH ZURICH (CH) 2022-01-13 — — US disclosed
CN-113387823-A Anthranilic acid and derivative thereof, and synthetic method and application thereof 华东师范大学 2021-09-14 — — CN disclosed
EP-3717464-B1 NITRATION ETH ZUERICH (CH) 2021-06-16 — — EP disclosed
EP-3717464-A1 NITRATION ETH Zurich (CH) 2020-10-07 — — EP disclosed
CN-104903321-B Three ring benzimidazoles are substituted as kinase inhibitor 赛尔维他股份公司 2017-10-24 — — CN disclosed
WO-2007064484-A2 ELECTROLUMINESCENT DEVICE CONTAINING A PHENANTHROLINE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 — — WO disclosed
WO-2007064484-A2 ELECTROLUMINESCENT DEVICE CONTAINING A PHENANTHROLINE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 — — WO disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 — — US disclosed
WO-1994028863-A1 8-AMINO-1,2,3,4-TETRAHYDROQUINOLINES AS COUPLERS IN DYES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1994-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009875-A1 NITRATION NOS1, NOS2, NOS3 TSHR 2432/4885PDE10A 2029/4885LMNA 4595/4885
US-11655203-B2 Nitration NOS1, NOS2, NOS3 TSHR 2432/4885PDE10A 2029/4885LMNA 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.